Biostage (BSTG) versus Nuvectra (NVTR) Head-To-Head Contrast

Nuvectra (NASDAQ:NVTR) and Biostage (OTCMKTS:BSTG) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, earnings and profitability.

Valuation & Earnings

This table compares Nuvectra and Biostage’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Nuvectra $31.84 million 7.67 -$44.60 million ($4.22) -3.28
Biostage $80,000.00 181.24 -$11.91 million N/A N/A

Biostage has lower revenue, but higher earnings than Nuvectra.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Nuvectra and Biostage, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nuvectra 0 0 4 0 3.00
Biostage 0 0 0 0 N/A

Nuvectra presently has a consensus price target of $24.00, suggesting a potential upside of 73.16%. Given Nuvectra’s higher probable upside, equities research analysts clearly believe Nuvectra is more favorable than Biostage.

Volatility and Risk

Nuvectra has a beta of 0.11, indicating that its stock price is 89% less volatile than the S&P 500. Comparatively, Biostage has a beta of 2.58, indicating that its stock price is 158% more volatile than the S&P 500.

Insider and Institutional Ownership

78.4% of Nuvectra shares are owned by institutional investors. Comparatively, 0.2% of Biostage shares are owned by institutional investors. 4.6% of Nuvectra shares are owned by company insiders. Comparatively, 6.5% of Biostage shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Nuvectra and Biostage’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Nuvectra -87.94% -65.86% -36.96%
Biostage N/A -224.68% -138.88%

Summary

Nuvectra beats Biostage on 6 of the 11 factors compared between the two stocks.

Nuvectra Company Profile

Nuvectra Corporation, a neuromodulation medical device company, develops and commercializes neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets. It operates through two segments, Nuvectra and NeuroNexus. The company offers Algovita spinal cord stimulation system that is used for the treatment of chronic pain of the trunk and limbs. It also designs, manufactures, and sells neural interface technologies, including microelectrode arrays, custom designed probes, and electrode instrumentation and accessories; and develops Virtis, a sacral neuromodulation system for the treatment of chronic urinary retention and overactive bladder. The company serves hospitals, surgery centers, and medical facilities through a direct sales force and third-party distributors in the United States and Europe. Nuvectra Corporation was founded in 2008 and is headquartered in Plano, Texas.

Biostage Company Profile

Biostage, Inc., a biotechnology company, engages in developing bioengineered organ implants based on its Cellframe technology. The company's Cellframe technology combines a proprietary biocompatible scaffold with a patient's own stem cells to create Cellspan organ implants. It is developing bioengineered organ implants, which addresses the damage of the esophagus, bronchus, and trachea due to cancer, infection, trauma, or congenital abnormalities. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2007 and is headquartered in Holliston, Massachusetts.

Receive News & Ratings for Nuvectra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply